Fig. 3From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyPFS in patients with brain metastases (A; median follow-up was 54.7 months in patients with low NLR, and was not available for those with high NLR) and without brain metastases (B; median follow-up was 44.8 months in patients with low NLR, and was not available for those with high NLR); OS in patients with brain metastases (C; median follow-up was 54.7 months in patients with low NLR, and was not available for those with high NLR) and without brain metastases (D; median follow-up was 51.8 months in patients with low NLR, and 75.7 months in those with high NLR), according to high or low baseline NLRBack to article page